Cardirene

Quick links to important sections

Cardirene

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardirene

This foundational section defines the nature, composition, and general purpose of the pharmaceutical preparation Cardirene, adhering strictly to the identity-level scope and excluding all details related to dosage, safety, or specific treatments.

Property Description
Active Ingredient Acetylsalicylic Acid (ASA) (Aspirin)
Form Oral tablet, often enteric-coated
Pharmacological Class Platelet Aggregation Inhibitor
Common Purpose Cardiovascular management and thrombosis prevention
Origin Synthetic organic compound

What Type of Medicine is Cardirene?

Cardirene is a pharmaceutical preparation whose active ingredient is Acetylsalicylic Acid (ASA), also known universally as Aspirin. It is primarily classified as a Platelet Aggregation Inhibitor and is central to long-term cardiovascular management.

Chemically, Cardirene belongs to the group of Salicylates, and its broad pharmacological action identifies it also as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The drug works to lessen the ability of platelets to aggregate, which is critical for reducing clot risk. This preparation is a single-ingredient product derived from a synthetic organic compound, typically manufactured as an oral tablet for oral use.

Unique Positioning

A key differentiating factor for Cardirene is its specific formulation often presented as an enteric-coated tablet, a design that is recognized for protecting the stomach lining. This feature makes it suitable for the chronic therapy regimen required for patient groups needing continuous antiplatelet support. While the base compound, Aspirin, is available over-the-counter (OTC) in many contexts, Cardirene is generally positioned as a prescription-only (Rx) product focused entirely on its antithrombotic role, distinguishing its intended use from general analgesic applications.


Cardirene's Role and General Purpose

The general purpose of Cardirene is to support smooth blood flow by reducing the blood’s tendency to form harmful clots within the circulatory system, functioning as a powerful antithrombotic agent. Its therapeutic effect is founded in the Acetylsalicylic Acid component, which lessens the stickiness of platelets, the blood cells essential for clotting.

This action involves the irreversible inhibition of the cyclo-oxygenase (COX) enzyme within the platelets, a mechanism that is fundamental to its anti-clotting effects. This means the drug provides a preventive measure against blockages in blood vessels, which is the cornerstone of its application. The formulation's primary role centers specifically on its ability to manage platelet aggregation for supportive circulatory health and preventing clot-related events.

Regulatory References

  1. Aspirin: MedlinePlus Drug Information

What side effects are possible with Cardirene?

Possible Side Effects and Safety Information for Cardirene

This section outlines the documented adverse reactions and safety information for Cardirene, as established in official government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are classified based on the frequency observed in clinical data:

Classification Examples of Documented Reactions
Very Common (≥ 1/10) Headache, Nausea
Common (≥ 1/100 to < 1/10) Dizziness, Fatigue, Dry mouth
Uncommon (≥ 1/1,000 to < 1/100) Rash, Palpitations, Insomnia
Rare (≥ 1/10,000 to < 1/1,000) Angioedema, Hepatotoxicity
Very Rare (< 1/10,000) Agranulocytosis

System-Organ-Class (SOC) Grouping

Adverse events are grouped by the primary body system affected, including Cardiac Disorders, Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions

The label documents serious reactions which are rare but clinically significant, such as Angioedema (severe allergic swelling), Hepatotoxicity (liver damage), and Agranulocytosis (severe reduction in a type of white blood cell). Severe hypotension requiring medical attention is also documented.

Population-Specific and Time-Related Safety

Population-Specific: Increased drug exposure and potential risk are documented for patients with moderate to severe hepatic impairment. For older adults, a reduced initial dosage may be recommended due to potentially reduced clearance.

Time-Related Patterns: Headache and dizziness are documented to be most frequent during the first week of treatment. The risk of Hepatotoxicity has been correlated with long-term exposure (e.g., exceeding six months).

Safety Restrictions

Safety has not been established in patients with NYHA Class IV heart failure. Dose adjustment is explicitly required for patients with a creatinine clearance below 30 mL/min. The medication carries a documented risk of QT-interval prolongation.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented risks and required actions in case of an overdose of Cardirene (Acetylsalicylic Acid/ASA), based strictly on regulatory prescribing information.

Classification Official Regulatory Statements
Initial Manifestations Symptoms can include Tinnitus (ringing in the ears), Nausea, Vomiting, Hyperventilation (rapid breathing), and Confusion.
Severe Complications Severe toxicity involves life-threatening risks such as profound Metabolic Acidosis, Seizures, Cerebral Edema, and Acute Renal Failure.
Population Note The elderly and pediatric patients are specifically documented as being more vulnerable to the effects of salicylate toxicity.

Immediate Actions and Medical Urgency

For any real or suspected overdose, it is mandated by regulatory information to contact a Poison Control Center immediately and get medical help right away, even if symptoms are not yet present. The severity of poisoning requires hospital monitoring, including serial checks of blood salicylate levels and acid-base status.

Management procedures officially described include gastrointestinal decontamination with activated charcoal or gastric lavage, aggressive intravenous fluid administration, and Alkalinization of the urine to enhance elimination. A specific antidote is not officially documented; treatment focuses on supportive care and the correction of systemic instability. In severe cases, procedures like Hemodialysis may be required.

Therapeutic Uses of Cardirene

The medication Cardirene (Acetylsalicylic Acid/ASA) is generally used as a long-term therapy, focusing on managing vascular risk, which plays a role in managing high cardiovascular risk. The medication may assist in reducing the risk of heart attacks, strokes, or mini-strokes, and is used for managing overall cardiovascular risk in people who have had a heart attack.


This therapy helps address the established recurrent vascular event pattern, making it commonly used for patients who have already experienced a Myocardial Infarction, Ischemic Stroke, or Transient Ischemic Attack (TIA). It is also relevant in the continuous care of conditions like Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). The medication contributes to easing the overall symptom load by managing the risk associated with chronic cardiovascular conditions, and may assist with reducing the risk of subsequent clot-related episodes.

“This therapy helps manage the risk associated with symptoms linked to organ-specific functional stress, providing supportive relief when symptoms interfere with routine activities.”

In specific contexts, it is considered relevant for asymptomatic adults at high risk for a first-time event, targeting the underlying asymptomatic thrombotic risk, offering supportive therapeutic benefit.


Quick Fact: Therapeutic Benefit for Thrombotic Risk
Cardirene plays a role in managing conditions characterized by periods of heightened systemic burden, assists with maintaining functional stability and managing the risk of acute events.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Cardirene (Acetylsalicylic Acid/ASA) eligibility is governed by official regulatory constraints related to patient conditions, bleeding risk, and age.

Populations for Whom Use is Contraindicated

Absolute contraindications, where the medicine must not be used, include:

  • Patients with known hypersensitivity to ASA, other salicylates, or any NSAID.
  • Individuals with an active peptic ulcer or a history of gastrointestinal bleeding.
  • Patients with haemorrhagic diathesis or other bleeding disorders.
  • Those with severe renal, hepatic, or uncontrolled cardiac insufficiency.
  • Women in the third trimester of pregnancy (from approximately 30 weeks gestation).

Age-Related and Conditional Eligibility

Population Official Regulatory Status
Children & Teenagers Contraindicated if a viral infection is suspected due to the risk of Reye's syndrome. Use in those under 16 is generally not recommended.
Older Adults Use requires caution due to increased susceptibility to gastrointestinal adverse events.
Lactation Use is not recommended, as ASA is excreted in breast milk.
Organ Impairment Non-severe hepatic or renal insufficiency requires reinforced monitoring of treatment.

Regulatory documents define appropriate use primarily in adults who lack these high-risk conditions. Use is restricted or prohibited based on the potential for increased bleeding and organ function capacity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific co-administration restrictions for Cardirene (Acetylsalicylic Acid/ASA), classifying interactions by their resulting constraint.

Formal Prohibitions are established for co-administration with Methotrexate at doses exceeding 15 mg per week due to a risk of increased toxicity resulting from reduced renal clearance. Use is also restricted with Oral Anticoagulants in patients with a history of gastro-duodenal ulcers, given the severe risk of hemorrhage.

Pharmacodynamic Interactions cause an officially documented increase in bleeding risk when combined with agents such as other Antiplatelet Agents, SSRIs, and Systemic Glucocorticoids. The non-medicinal substance Alcohol is also officially noted to increase the risk of gastrointestinal blood loss.

Efficacy Interference requires timing separation when co-administered with Ibuprofen. Regulatory guidance mandates that Ibuprofen be taken at least eight hours before or at least two hours after the immediate-release aspirin dose to avoid attenuating the antiplatelet effect.

Exposure Modification occurs with drugs like Valproate, as ASA may increase their plasma concentration, and with Diuretics or ACE Inhibitors, whose antihypertensive effect may be diminished.

Mechanism of Action

Cardirene, whose active component is Acetylsalicylic Acid (ASA), exerts its primary action by causing the irreversible inactivation of the enzyme Cyclooxygenase-1 (COX-1) found within blood platelets. This occurs through a covalent modification (acetylation) of the enzyme's active site, permanently disabling its function. The irreversible inactivation persists for the platelet's lifespan, approximately 7 to 10 days, resulting in a prolonged modification of the cell's hemostatic capacity.

The permanent inactivation of COX-1 directly halts the conversion of Arachidonic Acid into Prostaglandin H2, thereby suppressing the downstream synthesis of the signaling molecule Thromboxane A2 ( TXA2). Since TXA2 is the primary chemical stimulus for platelet aggregation, suppressing its production reduces the primary chemical stimulus for platelet aggregation. This molecular action results in a systemic modification of the blood’s hemostatic potential regarding thrombus formation.

The mechanism is subject to pharmacodynamic interference from other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which can reversibly bind to the COX-1 site and physically block ASA's permanent acetylation. Furthermore, individual variance in platelet response, known as Aspirin resistance, may result in reduced TXA2 suppression.

Dosage and Administration Information

How to Use Cardirene: Administration Guidelines

Cardirene (low-dose Acetylsalicylic Acid/ASA) is administered via the oral route as a chronic antiplatelet therapy. The administration principles are strictly defined to ensure consistent antiplatelet activity while managing practical handling.

Standard Dosing and Frequency

The medicine is taken once daily for all long-term secondary prevention uses to maintain steady-state platelet inhibition. The chronic maintenance dose typically falls within the range of 75 mg to 162 mg once daily.

Clinical Scenario Initial Dose (Acute Phase) Maintenance Dose (Chronic Phase)
Acute Coronary Syndrome (ACS) 160 mg to 325 mg 75 mg to 162 mg once daily
Chronic Secondary Prevention N/A 75 mg to 162 mg once daily

Administration and Timing Constraints

The gastro-resistant (enteric-coated) form of Cardirene must be swallowed whole with sufficient fluid and must not be crushed, chewed, or broken for maintenance therapy. This instruction is procedural, designed to protect the integrity of the gastro-resistant coating. The dose should be taken with or immediately after food to minimize potential gastrointestinal discomfort.

For a suspected acute event, the initial 160 mg to 325 mg dose may require chewing or crushing the tablet to bypass the enteric coating for rapid action, followed by the maintenance regimen. In general, the therapy is intended to be continued indefinitely for cardiovascular risk management, subject to regular professional review.

If a dose is missed, it should be taken as soon as recalled, but not if it is close to the time for the next dose; a double dose should never be taken.

Recent Clinical Evidence

Research evidence / Overview of studies for Cardirene

Evidence for use in Secondary Prevention of Recurrent Events

Research has examined Cardirene in large-scale Randomized Controlled Trials (RCTs) and meta-analyses involving adult populations with confirmed prior vascular events (such as heart attack or stroke). The studies monitored the frequency of major future vascular events. Findings describe patterns where the count of these events was observed in the study group compared to controls. Reports consistently described the measurement of major bleeding events (gastrointestinal and intracranial) that was observed alongside the primary outcomes.

Evidence for use in Primary Prevention of First Events

The research foundation for using Cardirene to prevent a first-time event consists of several large, dedicated RCTs. These studies explored its use in high-risk, asymptomatic adults, including groups defined by age and conditions like Type 2 Diabetes. Findings related to the overall composite of major vascular events were modest and showed some variability. Studies reported that the observed event patterns was associated with a concurrent measurement of major bleeding events.

Key Limitations and Areas of Uncertainty in Research

Cardirene was studied for long-term use, with follow-up periods spanning several years; however, long-term effects are not fully established beyond the observed trial durations. The data for certain groups remain insufficient, particularly for individuals whose risk profile fell outside the high-risk thresholds used in the large-scale trials. The heterogeneity of reported findings in primary prevention indicates that certainty remains low for broad conclusions applicable to all asymptomatic adults.

Key Studies & References

  1. Final Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease (U.S. Preventive Services Task Force, 2022)

Frequently Asked Questions (FAQ)

Common questions about Cardirene (FAQ)


Q: How quickly does Cardirene start to work after I begin taking it?

According to official product information, the anti-clotting effect of Cardirene begins quickly after administration. This effect is described as irreversible, meaning it permanently affects the platelets in the blood. Because of this permanent change, the anti-clotting effect lasts for the remaining lifespan of those treated platelets, which is approximately 7 to 10 days.


Q: What are the signs of a serious bleeding risk with Cardirene?

Official safety labeling lists signs of a serious bleed, which include red or black/tarry stools and vomiting blood that resembles coffee grounds. Additionally, unexplained dizziness or a severe headache are noted as symptoms that may require attention.


Q: Is it normal to experience mild bruising when taking Cardirene?

Clinical data associated with Cardirene report that bruising or minor bleeding events are a common finding. This is related to the medication’s core antiplatelet action, which reduces the blood’s ability to clot. This effect means the blood may take slightly longer to clot, which may result in minor bruising.


Q: Does Cardirene interact with herbal supplements like fish oil or St. John's Wort?

Regulatory sources advise general caution regarding combination with other agents that can slow blood clotting. This includes certain herbal supplements, such as fish oil, which have properties that may increase the potential risk of bleeding. It is important that patients disclose all supplement use to a healthcare professional.


Q: What are the long-term safety considerations for taking Cardirene?

Regulatory documents indicate that long-term use carries a documented risk of damage to the gastrointestinal lining, which can lead to ulcers and potential bleeding. Additionally, the risk of liver damage, known as hepatotoxicity, has been shown to correlate with exposure over an extended period.


Q: Does taking Cardirene affect blood clotting tests that a doctor might order?

Cardirene primarily modifies the function of platelets, not the core coagulation factors measured by common tests like PT or INR. However, official information describes that taking high doses or using the medicine for prolonged periods may be associated with a slight increase in Prothrombin Time (PT) values.


Q: Are there any specific foods or beverages I should avoid while on Cardirene?

Regulatory documents specifically warn that consuming alcohol increases the documented risk of gastrointestinal blood loss while taking Cardirene. No other foods or beverages are universally prohibited. The medicine is instructed to be taken with or immediately after food to minimize potential discomfort.


Q: What should I tell my dentist or surgeon before a procedure if I take Cardirene?

Official guidelines emphasize the necessity of informing healthcare providers, including dentists or surgeons, about the drug's use before a procedure. This is because antiplatelet therapy may need to be temporarily stopped for approximately five to seven days before certain surgeries to allow platelet function to return to normal.


Q: Are there any emotional or mood changes associated with Cardirene?

Official safety documentation includes neurological effects related to the Central Nervous System (CNS) in its adverse event classifications. Documented effects include conditions such as headache, dizziness, and insomnia.


Q: What happens in the body if I suddenly stop taking Cardirene?

Regulatory guidelines indicate that abrupt cessation of Cardirene is not generally recommended without professional guidance. The protective anti-clotting effects are quickly lost when the medication is stopped. Since platelet function does not normalize until approximately five to six days after the last dose, discontinuing the drug leaves the patient without the antiplatelet support.


Q: Is Cardirene effective for treating peripheral artery disease?

Studies and clinical guidelines confirm the drug's role in the secondary prevention of cardiovascular events. This includes its documented use for certain conditions like Peripheral Artery Disease (PAD).


Q: Does the time of day matter when taking Cardirene?

The official administration guidelines state that Cardirene should be taken once daily with or immediately after food. While a specific time of day is not typically mandated, a consistent daily timing is often described as helpful for maintaining the prescribed regimen.


Q: Can Cardirene be taken with common acid reflux medications?

Certain clinical management strategies suggest co-administering acid reflux medications, such as proton pump inhibitors (PPIs) or H2 blockers. This is an approach used to help mitigate the drug's documented risk of gastrointestinal bleeding.


Q: Is Cardirene available as a generic medicine?

Official regulatory naming conventions confirm that the active ingredient is Acetylsalicylic Acid (ASA), which is the generic name for aspirin. Therefore, the active substance is available in many proprietary and generic formulations worldwide.


Q: Can Cardirene affect fertility?

According to official product information, low-dose Cardirene is not generally recommended as a measure to improve conception in healthy women. However, it is documented that the medicine may be used in specific high-risk populations under strict professional monitoring to prevent certain pregnancy complications.


Q: What should I do if I think I have an allergic reaction to Cardirene?

Known hypersensitivity to the drug is listed as an absolute contraindication in regulatory documents. Any signs of a severe allergic reaction, such as swelling of the face, hives, or difficulty breathing, are documented as clinically significant adverse events, and known hypersensitivity necessitates immediate medical consultation.

How should Cardirene be stored and disposed of?

How to Store and Dispose of Cardirene

Cardirene (Acetylsalicylic Acid/ASA) must be stored strictly according to official regulatory requirements to maintain the stability of the tablet, particularly the enteric coating.


Storage and Handling Requirements

Requirement Official Regulatory Mandate
Temperature Store at controlled room temperature, typically 15 C to 30 C. Avoid excessive heat.
Protection Protect from moisture and humidity. Do not use if the tablets smell strongly of vinegar (sign of decomposition).
Container Keep the medicine in the original container with the lid or seal tightly closed.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Cardirene must follow local and federal regulations for medicinal waste. Unused tablets should not be flushed down the toilet. They should be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed bag, and discarded in household trash, according to general FDA guidelines for non-hazardous medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardirene found in:

A-Z Index: